BioCentury | Apr 15, 2013
Company News

PDT cancer news

...name to Miravant Medical Technologies, and will begin trading under the NASDAQ ticker symbol MRVT. PDT Inc....
BioCentury | Apr 15, 2013
Company News

PDT, Ramus Medical Technologies deal

...the company. PDTI hopes to enter clinical trials with the combined product within a year. PDT Inc....
BioCentury | Apr 21, 1997
Clinical News

SnET2 photodynamic therapy: Phase I and II Update

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2 photodynamic therapy Indication: Cutaneous breast cancer Status: PDTI expanded its Phase II/III trial to include a broader patient population. The trial now will accept patients on other...
BioCentury | Jan 20, 1997
Clinical News

SnET2 (tin ethyl etiopurpurin), a light-activated drug: Phase I and II Update

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2 (tin ethyl etiopurpurin), a light-activated drug Indication: Breast cancer and basal cell carcinoma Status: PDTI began Phase II/III trials with its SnET2 photodynamic therapy in France for...
BioCentury | Dec 23, 1996
Clinical News

PDT regulatory update

...compliance with general manufacturing and medical device quality standards for manufacturers selling products in Europe. PDT Inc....
BioCentury | Sep 3, 1996
Company News

PDT, Pharmacia & Upjohn deal

...Phase I/II trials for age-related macular degeneration and Phase II/III trials for certain skin cancers. PDT Inc....
BioCentury | Jul 15, 1996
Clinical News

SnET2 photodynamic therapy agent data

...laboratory measures. The agent is in Phase II/III trials. Pharmacia & Upjohn has marketing rights. PDT Inc....
BioCentury | Jun 24, 1996
Company News

PDT other research news

...surgery. SnET2 is in Phase I/II trials to treat complications of advanced age-related macular degeneration. PDT Inc....
BioCentury | Jun 3, 1996
Company News

PDT, IRIDEX Corp. deal

...source that PDTI is using in the Phase I/II trials of its SnET2 drug candidate. PDT Inc....
BioCentury | May 13, 1996
Clinical News

SnET2: PDTI began a Phase I/II dose escalation study of SnET2.

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2, photodynamic therapy Indication: Age-related macular degeneration Status: PDTI began a Phase I/II dose escalation study of SnET2. The therapy is designed to destroy abnormal blood vessels associated...
Items per page:
1 - 10 of 15
BioCentury | Apr 15, 2013
Company News

PDT cancer news

...name to Miravant Medical Technologies, and will begin trading under the NASDAQ ticker symbol MRVT. PDT Inc....
BioCentury | Apr 15, 2013
Company News

PDT, Ramus Medical Technologies deal

...the company. PDTI hopes to enter clinical trials with the combined product within a year. PDT Inc....
BioCentury | Apr 21, 1997
Clinical News

SnET2 photodynamic therapy: Phase I and II Update

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2 photodynamic therapy Indication: Cutaneous breast cancer Status: PDTI expanded its Phase II/III trial to include a broader patient population. The trial now will accept patients on other...
BioCentury | Jan 20, 1997
Clinical News

SnET2 (tin ethyl etiopurpurin), a light-activated drug: Phase I and II Update

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2 (tin ethyl etiopurpurin), a light-activated drug Indication: Breast cancer and basal cell carcinoma Status: PDTI began Phase II/III trials with its SnET2 photodynamic therapy in France for...
BioCentury | Dec 23, 1996
Clinical News

PDT regulatory update

...compliance with general manufacturing and medical device quality standards for manufacturers selling products in Europe. PDT Inc....
BioCentury | Sep 3, 1996
Company News

PDT, Pharmacia & Upjohn deal

...Phase I/II trials for age-related macular degeneration and Phase II/III trials for certain skin cancers. PDT Inc....
BioCentury | Jul 15, 1996
Clinical News

SnET2 photodynamic therapy agent data

...laboratory measures. The agent is in Phase II/III trials. Pharmacia & Upjohn has marketing rights. PDT Inc....
BioCentury | Jun 24, 1996
Company News

PDT other research news

...surgery. SnET2 is in Phase I/II trials to treat complications of advanced age-related macular degeneration. PDT Inc....
BioCentury | Jun 3, 1996
Company News

PDT, IRIDEX Corp. deal

...source that PDTI is using in the Phase I/II trials of its SnET2 drug candidate. PDT Inc....
BioCentury | May 13, 1996
Clinical News

SnET2: PDTI began a Phase I/II dose escalation study of SnET2.

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2, photodynamic therapy Indication: Age-related macular degeneration Status: PDTI began a Phase I/II dose escalation study of SnET2. The therapy is designed to destroy abnormal blood vessels associated...
Items per page:
1 - 10 of 15